OPEN ACCESS Freely available online

Journal of Cancer Science and Research

Perspective

Brief Note on Angiogenesis in the Pathophysiology of Lung Cancer

Jonle Dhyakon*

Department of Non-Communicable Diseases, Bangladesh University of Health Science, Dhaka, Bangladesh

ABOUT THE STUDY

Lung cancer remains one of the most common and dangerous forms of cancer globally, characterized by complex pathophysiological mechanisms. Understanding the complex processes that cause the development, progression of lung cancer is vital for advancing diagnostics, treatment, and prevention strategies. Lung cancer typically originates in the cells lining the bronchi and lungs. The disease manifests in various forms, primarily classified into two major types: Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). Each type has distinct pathophysiological features, influencing their behavior, prognosis, and treatment.

Non-Small Cell Lung Cancer (NSCLC)

NSCLC is responsible for approximately 85% of all lung cancer cases. It includes three primary subtypes: Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The pathophysiology of NSCLC involves various molecular alterations:

Genetic mutations: Genetic mutations in key genes play a vital role in the pathogenesis of NSCLC. The most common mutations occur in genes like *EGFR, KRAS, ALK, ROS1*, and others, contributing to uncontrolled cell growth and division.

Tumor suppressor genes: Inactivation of tumor suppressor genes, such as *TP53*, results in the loss of regulatory mechanisms that control cell proliferation and DNA repair, facilitating the development and progression of cancer.

Angiogenesis: Tumors stimulate the formation of new blood vessels through angiogenesis, providing a blood supply to sustain their growth and metastasis.

Small Cell Lung Cancer (SCLC)

SCLC includes a smaller percentage of cases. It is an aggressive form of lung cancer characterized by rapid growth and early metastasis.

Neuroendocrine origin: SCLC arises from neuroendocrine cells in the lung, exhibiting neuroendocrine features and often producing hormones, leading to paraneoplastic syndromes.

Rapid growth and metastasis: SCLC cells proliferate quickly and spread early to distant sites, contributing to its aggressive nature and limited treatment options at advanced stages.

Risk factors and carcinogenesis

Several risk factors contribute to the pathophysiology of lung cancer:

Smoking: Smoking is the leading cause of lung cancer. It is responsible for the majority of cases. Cigarette smoke contains carcinogens that can damage lung cells and lead to the development of cancer.

Radon gas exposure: Radon is a naturally occurring radioactive gas that can be absorbed into buildings. Prolonged exposure to high levels of radon is a known risk factor for lung cancer.

Air pollution: Prolonged exposure to high levels of air pollution, including particulate matter and other pollutants, is associated with an increased risk of lung cancer.

Family history and genetic factors: A family history of lung cancer may increase an individual's risk, suggesting a potential genetic predisposition. Specific genetic mutations, such as those in the *EGFR* (*Epidermal Growth Factor Receptor*) gene, are associated with an increased risk of lung cancer.

Immunological aspects

The immune system plays a important role in recognizing and eliminating abnormal cells, including cancer cells. Here are some immunological aspects related to the pathophysiology of lung cancer:

Immune evasion: Tumor cells can resist the immune system through various mechanisms, such as downregulating the expression of antigens and modulating immune checkpoints like PD-1 and PD-L1, inhibiting the immune response against cancer cells.

Correspondence to: Jonle Dhyakon, Department of Non-Communicable Diseases, Bangladesh University of Health Science, Dhaka, Bangladesh; E-mail: jd.123@gmail.com

Received: 24-Oct-2023, Manuscript No. JCSR-23-28018; **Editor assigned:** 26-Oct-2023; PreQc No. JCSR-23-28018 (PQ); **Reviewed:** 09-Nov-2023, Qc No. JCSR-23-28018; **Revised:** 16-Nov-2023, Manuscript No. JCSR-23-28018 (R); **Published:** 23-Nov-2023, DOI: 10.35248/2576-1447.23.8.559.

Citation: Dhyakon J (2023) Brief Note on Angiogenesis in the Pathophysiology of Lung Cancer. J Can Sci Res. 8:559.

Antigen presentation: Antigen-Presenting Cells (APCs) play a role in presenting cancer cell antigens to T cells, initiating an immune response. Deficiencies in antigen presentation can inhibit the recognition of cancer cells by the immune system.

Cytokines and chemokines: The release of certain cytokines and chemokines within the tumor microenvironment can influence the behavior of immune cells. For example, some cytokines promote an anti-tumor immune response, while others contribute to an immunosuppressive environment.

Tumor microenvironment

The tumor microenvironment in lung cancer can be immunosuppressive. It may contain immune cells, such as regulatory T cells and Myeloid-Derived Suppressor Cells (MDSCs), which suppress the activity of cytotoxic T cells that are responsible for killing cancer cells. It includes various cell types, extracellular matrix, and signaling molecules and influences the growth and spread of lung cancer:

Stroma and immune cells: Stromal cells and immune cells present in the tumor microenvironment interact with cancer cells, affecting tumor growth, invasion, and response to therapy.

Extracellular matrix: Changes in the extracellular matrix, including fibrosis and remodeling, contribute to the tumor's ability to attack nearby tissues and metastasize.

Metastasis: Metastasis, the spread of cancer cells from the primary site to distant organs, is a important aspect of lung cancer pathophysiology. Cancer cells can disseminate through blood vessels or the lymphatic system, forming secondary tumors in organs like the brain, bones, and liver, leading to minor diagnoses and limited treatment options in advanced stages.

Diagnostic and therapeutic implications

Advances in understanding the pathophysiology of lung cancer have revolutionized diagnostics and treatment strategies:

Molecular profiling: Molecular testing of tumor tissue helps identify specific mutations or alterations, guiding targeted therapies and personalized treatment approaches.

Targeted therapies: Drugs targeting specific genetic mutations or pathways, such as EGFR inhibitors and ALK inhibitors, have shown important efficacy in subsets of NSCLC patients.

Immunotherapies: Immune checkpoint inhibitors have revolutionized treatment by connecting the immune system to fight cancer, demonstrating favorable results in certain patients.

CONCLUSION

The pathophysiology of lung cancer is a complex process influenced by a combination of environmental, genetic, and lifestyle factors. The primary risk factor remains tobacco smoke, with carcinogens causing genetic mutations and cellular damage in the lung tissue. Also, exposure to secondhand smoke, radon gas, occupational carcinogens, and air pollution contribute to an increased risk. Genetic factors, including ancestral predisposition and specific gene mutations, play a role in susceptibility. The immune system, designed to recognize and eliminate abnormal cells, encounters challenges in the tumor microenvironment, leading to immune evasion and dysfunction. Understanding these complicated mechanisms is fundamental for developing targeted therapies, such as immunotherapy, and advancing strategies for prevention, early detection, and personalized treatment of lung cancer. Continued research and comprehensive approaches are essential to addressing this complex disease and improving outcomes for individuals affected by lung cancer.